Kornimate/medical-research-clean huggingface dataset:
long-des vi (drug eluting stent for long lesions in coronary artery)

Conditions: Coronary Artery Disease

Summary: this is a multi-center, randomized, study to compare the efficacy of zotarolimus-eluting stent (resolute integrity or resolute onyx stent) or everolimus-eluting stent (xience prime or xience xpedition or xience alpine stent) for very long coronary lesions.

following angiography, patients with significant diameter stenosis \> 50% and lesion length (\> 50mm) requiring at least 2 multiple long-stent placement by visual estimation and eligible for long-des vi trial inclusion and exclusion criteria will be randomized 1:1 to zotarolimus-eluting stent (resolute integrity or resolute onyx stent) or everolimus-eluting stent (xience prime or xience xpedition or xience alpine stent) by the stratified randomization method.

Eligibility criteria:
inclusion criteria: * age more than 20 years * significant native coronary artery stenosis (\> 50% by visual estimate) with lesion length of more than 50mm, which requires at least 2 multiple long stent placement without intervening normal segment * patients with silent ischemia, stable or unstable angina pectoris, and non-st-elevation myocardial infarction (nstemi) * the patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate institutional review board/ethical committee of the respective clinical site exclusion criteria: * any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, zotarolimus, or everolimus * an elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment * acute st-segment-elevation mi or cardiogenic shock * terminal illness with life expectancy \< 1 year * patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period * in-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment) however, non-target vessel in-stent restenosis is permitted * patients with ef \< 30% * serum creatinine level \>=2.0mg/dl or dependence on dialysis * patients with left main stem stenosis (\> 50% visual estimate)

Keywords: long lesions drug eluting stents
narrow band imaging bronchoscopy during sars-cov2 infection

Conditions: Covid19; Bronchoscopy; Narrow-band Imaging

Summary: vascular modifications have been described during sars-cov2 infection, especially a dilatation of the bronchial arteries. within the airway wall, small branches of the bronchial arteries cross the muscle layer to develop a submucosal network. the narrow band imaging technique is used during bronchoscopy to achieve a maximum contrast of vessels and the surrounding mucosa. therefore, it enables to observe the microvessel structure and its distribution in the bronchial mucosa. the aim of this study is to describe the vasculature pattern of the bronchial tree during infection with sars-cov2.


Eligibility criteria:
inclusion criteria: * patients who undergo bronchoscopy with image and/or videos recording of nbi aspect of the proximal bronchial tree (carina, right and left upper lobe). * patients hospitalized with sars-cov2 infection proven by rt-pcr test * patients hospitalized with lower respiratory tract infections unrelated to sars-cov2 (rt-pcr negative for sars-cov2) * patients who have had bronchoscopy performed as part of the assessment of a distal pulmonary nodule (rt-pcr negative for sars-cov2). exclusion criteria: * patients under legal protection * patients who refuses the use of his personal medical data

Keywords: covid19 bronchoscopy narrow-band imaging bronchial vasculature acute vascular distress syndrome
phase 1 safety and tolerability of medi4736 in combination with dabrafenib and trametinib or with trametinib alone

Conditions: Melanoma

Summary: the purpose of this study is to determine the maximum tolerated dose and characterize the safety profile of durvalumab (medi4736) in combination with dabrafenib and trametinib or with trametinib alone in participants with metastatic or unresectable melanoma with braf-mutation positive or wild-type (wt) braf, respectively.

this is a multicenter, open-label study with a dose escalation phase followed by an expansion phase of durvalumab administered in combination with dabrafenib and trametinib or with trametinib alone in participants with braf v600 mutation-positive and wt unresectable or metastatic melanoma, respectively.

Eligibility criteria:
inclusion criteria: * adults \>= 18 years old * histologically confirmed cutaneous melanoma that is either stage iiic (unresectable) or stage iv (metastatic) and determined to be braf v600e or v600k mutation-positive (cohort a) or mutation-negative (cohorts b and c) * eastern cooperative oncology group (ecog) performance status of 0 or 1 * measurable disease by radiographic or physical examination * adequate organ and marrow function * willingness to provide consent for biopsies positive or braf wt measurable disease and adequate organ and marrow function exclusion criteria: * prior treatment with a braf inhibitor or mek inhibitor * any prior grade \>= 3 immune-related adverse event while receiving immunotherapy * active or prior documented autoimmune disease within the past 2 years * history of or current risk for retinal vein occlusion (rvo) or central serous retinopathy (csr) * history of or current cardiovascular risk including myocardial infarction, \>= class ii congestive heart failure, uncontrolled arrhythmias, or refractory hypertension * active, untreated central nervous system (cns) metastases * women who are pregnant or lactating

Keywords: metastatic or unresectable melanoma, durvalumab (medi4736), dafrafenib, trametinib, braf-mutation positive, wild-type braf, pd-l1, pd-1
vegf as a prognostic factor for white matter damage in preterm infants

Conditions: Preterm Infants With White Matter Damage; Preterm Infants Developing Normally

Summary: we hypothesize that misexpression of vascular endothelial growth factor (vegf) in the cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for developing white matter damage.


Eligibility criteria:
inclusion criteria: * preterm infants undergoing lumbar puncture. exclusion criteria: * preterm with ivh or known infection or meningitis.
study on brain network mechanism of deep brain stimulation for parkinson's disease

Conditions: Parkinson Disease; Deep Brain Stimulation; Non-motor Symptoms

Summary: as a surgical intervention, dbs can effectively relieve pd tremor, rigidity, bradykinesia and other symptoms. how to better screen patients suitable for dbs treatment and conduct reasonable preoperative and postoperative evaluation is crucial to judge the treatment effect and prognosis. the clinical symptom evaluation of pd patients can be divided into motor symptom evaluation and non-motor symptom evaluation. the motor symptoms of pd patients were evaluated by updrs iii. the evaluation of non-motor symptoms in pd patients was mainly divided into three aspects: cognitive status, emotional status, and sleep status. mini-mental state examination (mmse) and montreal cognitive assessment (moca) were used to assess the cognitive status of pd patients. the hamilton depression scale (hamd) was used to assess the patients' depression status. the hamilton anxiety scale (hama) was used to assess the patients' anxiety status. the pd sleep scale 2nd version, the pd sleep scale 2nd version, pdss - 2), and rem sleep behavior disorder questionnaire (sweet hk) (rapid eye movement sleep behaviors disorder questionnaire - hong kong, rbdq - hk) to assess sleep conditions.


Eligibility criteria:
inclusion criteria:the clinical diagnosis of pd is consistent with the united kingdom parkinson's disease society brain bank criteria, with disease duration over 5 years, age under 75, acute levodopa motor response ≥30%, and indication for stn-dbs. - exclusion criteria: patients with severe cognitive impairment, severe psychiatric disorders, acute levodopa motor response less than 30%, atypical parkinsonism, and contraindications to surgery -
safety study of cd-np in heart failure

Conditions: Congestive Heart Failure

Summary: an open-label study designed to determine the safety, tolerability and pharmacodynamics of cd-np infusions in heart failure patients.


Eligibility criteria:
key inclusion criteria: * male or female ≥18 years of age diagnosed with nyha class iii or iv heart failure in the last six months * female patients must be post-menopausal or surgically sterile * diagnosed heart failure with left ventricular ejection fraction \<40% obtained within the prior 6 months with at least one symptoms or signs of volume overload key exclusion criteria: * women who are pregnant, breast-feeding or of child-bearing potential * clinically unstable patients * major surgical procedures within 30 days of entry * febrile temp \> 100 degrees f) * symptomatic carotid disease, critical carotid stenosis, or stroke within 3 months prior to study entry * currently on iv vasoactive support (e.g., heart transplant candidate) * history of unexplained syncope within the past 3 months * history of organ transplantation * comorbidities such as clinically significant cardiac valvular stenosis, aortic valvular disease, restrictive cardiomyopathy, hypertrophic obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, infiltrative disease, uncorrected congenital heart disease, acute coronary syndrome, restrictive heart failure, or any other condition which, in the opinion of the investigator, would prevent a patient's participation in the study. * participation in a clinical trial of any investigational therapy or device within 30 days prior to randomization. * treatment with nesiritide within 14 days prior to dosing. * inability to effectively communicate with study personnel.

Keywords: heart failure cd-np
move and snooze: adding insomnia treatment to an exercise program to improve pain outcomes in older adults with knee osteoarthritis

Conditions: Knee Osteoarthritis; Insomnia

Summary: this research will compare the effectiveness of a remotely delivered personalized exercise coaching plus an evidence-based sleep improvement intervention to remotely delivered personalized exercise coaching alone for knee osteoarthritis pain. the study team hypothesize that the combined intervention will result in greater improvements in patient-reported pain intensity, recorded with real-time data capture, than remotely delivered exercise coaching alone.


Eligibility criteria:
inclusion criteria: * self-reported physician diagnosis of knee osteoarthritis * persistent knee osteoarthritis-related pain of at least moderate intensity (as indicated in the protocol) * indication of persistent symptoms of insomnia, determined by scoring on the sleep condition indicator questionnaire (as indicated in the protocol) * if receiving medication for pain or sleep disturbances, having had no change in prescription in the previous three months and be willing to make no other changes to medications for pain or sleep during the active study period. * adequate literacy level to ensure web-based surveys can be completed independently, as assessed using a brief 3-item literacy level screener exclusion criteria: * concurrent diagnosis of a systemic, inflammatory musculoskeletal disorder (e.g., rheumatoid arthritis) * active malignancy * neurological conditions (e.g., movement disorders) * any medical condition which would make graded increase of physical activity unsuitable (determined by a positive answer to the question: "has a doctor or healthcare professional advised you to avoid physical activity for any reason?"). * unable to understand english sufficiently to take part in the intervention. * unable to provide electronic informed consent. * evidence of significant cognitive impairment (i.e., ≥2 errors on a 6-item cognitive screener). * presence of severe psychiatric disorder. * currently participating in an interventional trial or a pain or sleep management program or having done so in the past six months. * visual or hearing impairment that would prevent use of the intervention. * serious physical health concerns necessitating surgery or with a prognosis \<6 months * irregular sleep-wake schedule, e.g., shift work. * self-report of diagnosis of a specific sleep disorder other than insomnia that is not currently adequately treated, e.g., sleep apnea or narcolepsy. * currently meeting or exceeding physical activity guidance from the u.s. department of health and human services (noted in protocol)

Keywords: exercise coaching cognitive behavioral therapy
evaluation of dysphagia by 6-chnnel surface electromyography

Conditions: Deglutition Disorders

Summary: the natural process of aging affects a few very specific timing parameters such as swallow reaction time and hyoid one movement velocity. many swallow timing and bolus transit parameters appear to be unaffected by aging. we want to know the changes of kinematic variables according to the aging process. first hypothesis: there are probably be a protection mechanism that blocks functional loss progressing to kinematic abnormality. muscle activation sequence change (i.e duration or amplitude) of the oropharyngeal muscles play an important role. second hypothesis: age-related differences in muscle activation patterns will also appear differently depending on the characteristics of swallowed food.

inclusion criteria inclusion criteria of healthy older adults : age \> 60, without dysphagia, comorbidity inclusion criteria of young control group : age \< 60, without dysphagia, comorbidity no prior history of swallowing difficulty or history of central nervous system disease, and none were taking medication that are known to affect swallowing. surface emg was performed at bilateral suprahyoid, thyrohyoid, sternothyroid and pharyngeal constrictors. the latency of activation and termination was checked.

Eligibility criteria:
inclusion criteria of old group * age \> 60, without dysphagia, comorbidity inclusion criteria of young control group * age \< 60, without dysphagia, comorbidity

Keywords: deglutition disorders electromyography
trial of ctdna of guidance to determine postoperative radiation therapy

Conditions: Lung Cancer; Non Small Cell Lung Cancer; Lung Cancer Recurrent

Summary: primary objective: evaluate the role of ctdna positivity in decision making for postoperative therapy for non-small cell lung cancer. the plan for postoperative therapy will be declared after pathology report review and before the ctdna result. we will assess if ctdna result changed the planned therapy. secondary objectives: evaluate personalized postoperative chemo/icpi/targeted therapies/radiation therapy in clearing ctdna evaluate the disease-free survival (dfs) and overall survival (os) of stage ii/iii lung cancer patients with postoperative ctdna positive status exploratory objective: evaluate radiomics features based on serial ct thoracic ct scans to determine if radiomic features can be associated with ctdna positivity/negativity.

this is a pilot, single-arm interventional study evaluating the use of the haystack™ circulating tumor dna (ctdna) assay to guide postoperative radiation therapy (port) and systemic therapy decisions for patients with stage ii-iii non-small cell lung cancer (nsclc) who have undergone surgical resection. the study aims to assess whether ctdna monitoring can effectively detect minimal residual disease (mrd) and improve post-surgical treatment strategies.

Eligibility criteria:
inclusion criteria: 1. have provided signed informed consent for the trial 2. aged ≥18 years at the time of informed consent 3. eastern cooperative oncology group (ecog) performance status of 0 or 1 4. diagnosed with histologically confirmed stage ii-iii nsclc and undergone surgical resection of lung tumor 5. no active second cancers/malignancy 6. patients that received preoperative therapy (including chemotherapy and immunotherapy or others) are eligible 7. willing and able to comply with all aspects of the protocol 8. standard of care therapy and methods as per institution and investigator discretion - exclusion criteria: exclusion criteria 1. discontinued treatment due to a grade 3 or higher aes with chemotherapy or immunotherapy or targeted therapy agent 2. with a history of another primary malignancy within the past 2 years that is considered an active malignancy by the enrolling physician. 3. have known active cns metastases and/or carcinomatous meningitis. 4. have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis. 5. have a history of interstitial lung disease. 6. have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator. -
ef5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer

Conditions: Stage I Adult Soft Tissue Sarcoma; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Adult Soft Tissue Sarcoma; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Adult Soft Tissue Sarcoma; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

Summary: this laboratory study is using ef5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. using the drug ef5 to measure the oxygen level in tumor cells may help in planning cancer treatment

primary objectives: i. determine biologically-relevant hypoxia by imaging and cellular analysis of ef5 binding in patients with high-grade soft tissue sarcoma of the trunk or extremity or squamous cell carcinoma of the oral cavity. ii. determine the spatial relationships between ef5 binding and various tumor tissue markers, pathological processes, and serum plasminogen activator inhibitor-1 in these patients. iii. correlate ef5 binding with eppendorf electrode measurement and patient-related factors in these patients. iv. determine the adjusted and unadjusted associations between clinical outcome and optimal measures of ef5 binding, patient/tumor characteristics, and biological markers in these patients. outline: approximately 24-48 hours prior to surgical resection or biopsy, patients receive ef5 iv over no more than 2½ hours. tissue samples are analyzed by immunohistochemistry for ef5 binding. blood samples are analyzed for genetic markers and cytokines associated with hypoxia and ef5 concentration.

Eligibility criteria:
inclusion criteria: * histologically confirmed high-grade soft tissue sarcoma (sts) of the trunk or extremity or squamous cell carcinoma of the oral cavity for which surgical biopsy or resection is standard initial therapy * clinical imaging of mass that is likely to be sts or squamous cell carcinoma of the head and neck allowed if surgery is indicated prior to definitive diagnosis * planned resection and standard oncologic treatment * no known distant metastatic disease * ecog 0-2 * wbc at least 2,000/mm\^3 * platelet count at least 100,000/mm\^3 * bilirubin less than 2.0 mg/dl * creatinine less than 2.0 mg/dl or creatinine clearance at least 50 ml/min * no significant cardiac condition that would preclude study compliance * weight no greater than 130 kg * no grade iii or iv peripheral neuropathy * no other medical condition that would preclude study compliance * not pregnant or nursing * fertile patients must use effective contraception * see disease characteristics * no chemotherapy within 3 months before planned surgery * preoperative radiotherapy allowed for sts * no radiotherapy within 3 months before planned surgery * no other concurrent investigational agents
acute effects of motor imagery and action observation in the elderly: single-blind randomized controlled trial

Conditions: Elderly (People Aged 65 or More)

Summary: the aim of this study is to investigate the effects of acute action observation, motor imagery, exercise, and combined exercise training on parameters such as balance, reaction time, flexibility, fear of falling, cognitive status, attention, and memory in older adults.

previous studies investigating motor imagery and action observation training have examined their long-term effects in both young and older adults. existing evidence regarding the benefits of exercise training indicates positive effects in both populations. however, the number of studies focusing on the acute effects of motor imagery and action observation training in the literature is very limited. individuals who meet the inclusion criteria will be randomly assigned-using the research randomizer application-into five groups: motor imagery, action observation, exercise, combined exercise, and control group. a total of 50 participants, with 10 individuals in each group, will be included in the study. assessments will be conducted before and after the intervention.

Eligibility criteria:
inclusion criteria: * being aged 65 years or older, female gender, literate in turkish, scoring 21 or above on the montreal cognitive assessment (moca) version 7.1, no health conditions that would prevent participation in exercise exclusion criteria: * presence of serious health problems that would prevent participation in the study (e.g., trauma, cancer, surgery, severe cardiac or musculoskeletal disorders) participation in other intervention trials or observational studies during the intervention period, or initiation of a physical exercise program within 2 weeks following the intervention period any medical condition or chronic medication use that may jeopardize safety or affect cognitive functions (e.g., neuroleptics)

Keywords: imagery mirror neurons exercise
machine learning to construct an association model for lung cancer and environmental hormone

Conditions: Lung Neoplasms

Summary: to apply machine learning to construct an association model regarding lung cancer and environmental hormones to more comprehensively identify factors that may lead to lung cancer and to improve existing lung cancer nursing assessments.

the present study is exploratory, and its design was divided into three stages: stage 1 explored the environmental hormonal risk factors for lung cancer and constructed an association model using machine learning algorithms. stage 2 validated the results of the association model with better predictive results in clinical settings. stage 3 involved recommendations for reconstructing nursing assessments based on the results of the clinical model validation. the three stages are summarized as follows.

Eligibility criteria:
inclusion criteria: 1. 20 years or older; 2. conscious, without mental disorders; 3. able to use mandarin to communicate, had a smartphone or tablet computer and could operate it by themselves, 4. and were willing to participate in the study after the reasons for participation were explained and a consent form was signed, indicating their consent. exclusion criteria: * the exclusion criteria were those who could not understand the content of the nursing assessment questions and those with mental disorders.

Keywords: environmental substance